Lipid management reduces cardiovascular complications in individuals with diabetes and prediabetes.
Patients with type 2 diabetes are known to have an elevated risk of cardiovascular morbidity and mortality. Prior to the development of hyperglycemia and type 2 diabetes, individuals undergo a prolonged prediabetic phase involving hyperglycemia and insulin resistance. This has been associated with increased cardiovascular risk and is considered a cardiovascular risk equivalent. It is well known that dyslipidemia is an important contributor to the development of coronary artery disease. Treating diabetes with lipid-lowering agents reduces patients' cardiovascular risk. Preliminary studies have shown that similar benefits are seen even in persons with prediabetes. Hence, lipid-lowering agents should be considered not only in patients with type 2 diabetes, but also in individuals with prediabetes and with elevated lipid levels.
Gosavi
Aparna
A
Department of Internal Medicine, University of Missouri, Columbia, Columbia, MO 65212, USA. agosavi03@yahoo.com
Flaker
Gregory
G
Gardner
David
D
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003324:Coronary Artery Disease / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006943:Hyperglycemia / Q000150:complications* / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D016032:Randomized Controlled Trials as Topic
D001786:Blood Glucose; D000960:Hypolipidemic Agents